A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization
Our models successfully predicted VE of the RSV maternal vaccines and have potential use in modeling the clinical trial out-comes of other respiratory disease vaccines where maternal antibodies play a role in the protection of newborns.
Authors
- Kenneth Koury
- Kena A. Swanson (ORCID: https://orcid.org/0000-0002-3389-8414)
- Philip R. Dormitzer (ORCID: https://orcid.org/0000-0003-0671-6360)
- Yasmeen Agosti
- William C. Gruber (ORCID: https://orcid.org/0000-0002-6518-4547)
- Beate Schmöele-Thoma (ORCID: https://orcid.org/0000-0003-4632-357X)
- Yili Chen (ORCID: https://orcid.org/0000-0002-1409-631X)
- Kathrin U. Jansen (ORCID: https://orcid.org/0000-0001-7818-8996)
- Bing Cai (ORCID: https://orcid.org/0000-0002-3632-9866)
Institutions
- Pfizer (United States) (US)
Publication Details
- Journal
- Vaccines
- Published
- 2024-11-29
- DOI
- https://doi.org/10.3390/vaccines12121351
- Citations
- 2
- Primary Topic
- Respiratory viral infections research
- Type
- article
- Field-Weighted Citation Impact
- 0.77
Funders
- Pfizer